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SUMMARY
Excess serum free fatty acids (FFAs) are fundamental to the pathogenesis of insulin resistance.
With high fat feeding, FFAs activate NF-κB in target tissues, initiating negative cross-talk with
insulin signaling. However, the mechanisms underlying FFA-dependent NF-κB activation remain
unclear. Here we demonstrate that the saturated FA, palmitate, requires Bcl10 for NF-κB
activation in hepatocytes. Uptake of palmitate, metabolism to diacylglycerol, and subsequent
activation of PKC appear to mechanistically link palmitate with Bcl10, known as a central
component of a signaling complex that, along with CARMA3 and MALT1, activates NF-κB
downstream of selected cell surface receptors. Consequently, Bcl10-deficient mice are protected
from hepatic NF-κB activation and insulin resistance following brief high fat diet, suggesting that
Bcl10 plays a major role in the metabolic consequences of acute overnutrition. Surprisingly, while
CARMA3 also participates in the palmitate response, MALT1 is completely dispensable, thereby
revealing an apparent non-classical role for Bcl10 in NF-κB signaling.
INTRODUCTION
The metabolic syndrome is a cluster of conditions that greatly increases the risk for type 2
diabetes mellitus (T2DM) and cardiovascular disease. A key component to the syndrome is
chronic overnutrition and development of obesity (Unger and Scherer, 2010). Changes in
adipose tissue that occur in central/visceral obesity contribute to a systemic, low-grade
inflammatory state now known as “metabolic inflammation” which impairs insulin signaling
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in key tissues including liver, skeletal muscle, and brain, thereby producing systemic insulin
resistance (Gregor and Hotamisligil, 2010).
While the insulin resistance associated with obesity unfolds over a long period of time and is
associated with changes in the cellular makeup and function of adipose tissue, there is also a
well-recognized short-term consequence of overnutrition that is likely due to the direct
effects of nutrient excess (Kleemann et al., 2010; Schenk et al., 2008). This is particularly
notable with the fat overnutrition that characterizes the Western diet. Under conditions of
moderate fat intake, lipoprotein lipase expressed in the microvasculature releases fatty acids
from triacylglycerols contained in circulating chylomicrons as a means for transferring
dietary lipids to adipocytes for subsequent storage (Miles and Nelson, 2007). In this way,
fatty acids obtained directly from the diet do not circulate freely, outside the confines of
chylomicrons or related lipoproteins. In contrast, even a single high fat meal results in an
increase in serum free fatty acids (FFAs), a consequence of the “spillover” effect whereby
the lipoprotein lipase-mediated release of fatty acids exceeds the capacity of fatty acid
uptake and storage in adipocytes (Miles and Nelson, 2007). This postprandial elevation in
serum FFAs is only compounded by visceral obesity because spillover rates are particularly
high in the splanchnic vascular bed, which expands to support the excess visceral fat
(Nelson et al., 2007; Nielsen et al., 2004). In this scenario, FFAs become a pathologic
nutrient, capable of disrupting metabolic homeostasis (Boden, 2011).
Hepatocytes are thought to be a major target for the deleterious effects of elevated FFAs, in
part because FFAs released in the splanchnic bed are delivered through the portal circulation
directly to the liver. Saturated FAs in particular activate the canonical NF-κB pathway in
liver, which then mediates inhibitory cross-talk at various steps in insulin signaling
pathways and causes hepatic insulin resistance (Baker et al., 2011). Despite the implications
for the pathogenesis of T2DM, the mechanisms by which FFAs activate NF-κB are still
unclear. There are likely multiple mechanisms at play, with increasing evidence suggesting
that cell type- and tissue-specific differences may exist with regard to FFA-dependent
signaling. Considerable data indicate that some FFAs act as ligands for toll-like receptor 4
(TLR4), expressed abundantly on macrophages, and therefore signal to NF-κB in a receptor-
dependent manner (Lee et al., 2001; Saberi et al., 2009; Shi et al., 2006). Other data suggest
that FFAs are taken up by target cells and undergo metabolism to produce signaling
intermediates, such as diacylglycerols (DAGs) and ceramides, which can then signal to NF-
κB through PKC intermediates (Erion and Shulman, 2010; Holland and Summers, 2008;
Turban and Hajduch, 2011). Finally, FFA metabolites may also induce endoplasmic
reticulum (ER) stress culminating in activation of kinases, such as the double-stranded
RNA-dependent protein kinase (PKR), that interface with the NF-κB pathway (Nakamura et
al., 2010; Ozcan et al., 2004). These mechanisms are not mutually exclusive and it is likely
that different cells utilize different mechanisms depending upon the cellular repertoire of
receptors, metabolic enzymes, and signaling intermediates.
In lymphocytes and some related immune cells, a critically important signaling event
mediating adaptive immunity involves activation of a signaling complex (CBM
signalosome) composed of a scaffolding protein, CARMA1, an adaptor protein, Bcl10, and
an effector protein, MALT1, that communicates with the NF-κB machinery. In
lymphocytes, assembly of the CBM signalosome first requires T or B cell receptor-
dependent PKC activation and phosphorylation of CARMA1 (Wegener and Krappmann,
2007). Recently, we found that the CBM signaling components are present in non-immune
cells including hepatocytes, with the highly homologous CARMA3 protein substituting for
CARMA1 (McAllister-Lucas et al., 2007). Further, activation of the receptor for angiotensin
II (AGTR1) on hepatocytes could also engage PKC-dependent CBM signaling and NF-κB
activation (McAllister-Lucas et al., 2007). As a result, we wondered if FFA-dependent
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activation of PKC, through generation of intermediates such as DAG or ceramide, might
harness the CBM signalosome as a means for activating NF-κB; this would represent the
first physiologic example of receptor-independent NF-κB activation through the CBM
signalosome. Results show that palmitate indeed activates NF-κB in hepatocytes in a Bcl10-
dependent manner. Intriguingly, while CARMA3 also participates in palmitate-dependent
NF-κB activation, MALT1 is completely dispensable. Further, Bcl10−/− mice are protected
from hepatic NF-κB activation following high-fat feeding, and are also protected from
systemic insulin resistance. These findings reveal a novel molecular mechanism through
which FFAs can communicate with the canonical NF-κB machinery.
RESULTS
Palmitate induces hepatocellular NF-κB with delayed kinetics
High fat feeding and obesity are associated with increased flux of FFAs into the circulation,
thereby leading to enhanced uptake of the fatty acids into multiple tissues, including the
liver. In order to mimic the influx of excess FFAs into hepatocytes, we treated human
HepG2 cells with palmitate, a saturated FA found abundantly in the Western diet. We
observed a time- and concentration-dependent induction of IκBα phosphorylation following
palmitate treatment, indicating activation of the canonical NF-κB pathway (Figures 1A and
S1A). In this pathway, stimulation of the multisubunit IκB Kinase (IKK) complex triggers
phosphorylation-dependent proteasomal degradation of IκBα thus releasing
transcriptionally active p50/RelA NF-κB dimers for translocation into the nucleus (Baker et
al., 2011). As such, we also observed palmitate-dependent nuclear accumulation of RelA
(Figure 1B). In addition, we demonstrated that IKK2 inhibitor VI, a selective inhibitor of the
canonical pathway-specific IKKβ subunit, blocks palmitate-induced IκBα phosphorylation,
as does siRNA-mediated knockdown of IKKβ protein (Figures 1C and 1D).
Interestingly, NF-κB activation occurred much more slowly in response to palmitate as
compared to interleukin-1β (IL-1β) (Figure 1A). IL-1β, a pro-inflammatory cytokine whose
level is elevated during obesity, induces canonical NF-κB activation in hepatocytes via
stimulation of its receptor, IL-1R (Schroder et al., 2010). IL-1β treatment of hepatocytes
induced robust phosphorylation of IκBα within 5 minutes, typical for a receptor-mediated
response. In contrast, no significant phosphorylation of IκBα or RelA nuclear translocation
was observed until after 60 minutes of palmitate treatment, with peak activation occurring
between 90 and 120 minutes. This difference in the time course suggests that palmitate
stimulates canonical NF-κB signaling via a mechanism that is distinctly different from that
used by IL-1β, and may indicate that palmitate-dependent activation of NF-κB does not
occur via traditional receptor-mediated intracellular signaling.
Neither TLR4, nor an IL-1β/IL-1R autocrine loop, mediate palmitate-dependent NF-κB
activation in hepatocytes
We then investigated whether TLR4, a pattern recognition receptor implicated in FFA-
dependent signaling in macrophages, myocytes, and adipocytes (Fessler et al., 2009), is
required for palmitate-induced canonical NF-κB activation in hepatocytes. Previous gene
expression profiling studies had shown that TLR4 expression is quite low in the liver, as
compared to several other tissues (Lattin et al., 2008; Wu et al., 2009). In particular,
expression in liver cells is several orders of magnitude lower than in macrophages,
myoblasts, and adipocytes (Figure S1B). Furthermore, high throughput analysis of gene
transcriptional responses has revealed that treating primary rat hepatocytes with the classic
TLR4 agonist, lipopolysaccharide (LPS), does not induce a notable NF-κB gene expression
signature (Deng et al., 2010). With this in mind, we first evaluated the response of HepG2
cells to LPS; these cells represent a good model for testing hepatocellular sensitivity to bona
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fide TLR4 agonists because, albeit low, levels of TLR4 and its downstream signaling
intermediates such as Myd88 are comparable in HepG2 cells and in primary hepatocytes
(Liguori et al., 2008). We found that, even at high doses, LPS does not stimulate canonical
NF-κB signaling in HepG2 cells (Figure S1C), consistent with what has been seen with a
range of other hepatocyte cell lines (Preiss et al., 2008). Second, we demonstrated that α-
TLR4, a receptor-blocking antibody that prevents LPS-mediated NF-κB activation in
MonoMac-6 macrophages, has no effect on palmitate-induced IκBα phosphorylation in
HepG2 cells (Figure 1E). Together, our results and the gene expression profiling studies
suggest that the TLR4 signaling machinery is not robustly active in hepatocytes and that
palmitate does not utilize TLR4 to stimulate canonical NF-κB activation in these cells.
Recent reports demonstrate that palmitate can induce activation of the NLRP3
inflammasome in macrophages and in liver (Csak et al., 2011; Vandanmagsar et al., 2011;
Wen et al., 2011). Inflammasomes are large multi-protein complexes that, when activated by
exogenous or endogenous “danger signals” such as cholesterol crystals, uric acid crystals
and amyloid-β protein, stimulate the cleavage of pro-IL-1β, thereby promoting maturation
and secretion of active IL-1β (Davis et al., 2011). This could potentially establish a feed-
forward, inflammatory loop due to autocrine IL-1β-dependent NF-κB activation. We
therefore investigated whether the palmitate-dependent NF-κB activation we observed in
hepatocytes occurs via an IL-1β autocrine loop, a finding that might account for the time
delay required for NF-κB activation. However, we found that while an IL-1R antagonist
peptide (IL-1RA) completely prevents NF-κB activation in hepatocytes treated with IL-1β,
the peptide has no effect on palmitate-dependent NF-κB activation (Figure 1F).
Taken together, these results indicate that the striking time delay required for palmitate-
dependent NF-κB activation is not explained by an IL-1β autocrine loop, nor is it consistent
with a direct, receptor-mediated response to palmitate, as might occur if TLR4 was present
on hepatocytes and capable of recognizing palmitate as an agonist. Instead, we reasoned that
the delay might reflect the need for internalization and metabolism of palmitate into
signaling intermediates capable of stimulating the NF-κB machinery.
Palmitate-dependent canonical NF-κB activation in hepatocytes requires DAG-dependent
stimulation of PKC, but not ceramide production
Upon entering the cell, palmitate can be incorporated into either of two bioactive
metabolites that have been implicated in NF-κB stimulation and insulin resistance, DAG or
ceramide (Figure 2A) (Deevska and Nikolova-Karakashian, 2011). In order to determine if
ceramide production contributes to the observed palmitate-induced NF-κB activation in
hepatocytes, we evaluated the effect of myriocin, an inhibitor of the rate-limiting enzyme in
ceramide synthesis, serine palmitoyltransferase (SPT) (Summers, 2010). While myriocin
completely prevented palmitate-dependent increases in intracellular ceramide species, it had
no effect on palmitate-dependent IκBα phosphorylation (Figure 2B). Similarly, cycloserine
and fumonisin B1, two other inhibitors of enzymes catalyzing committed steps in ceramide
synthesis, had no effect on palmitate-dependent IκBα phosphorylation (Figure S2). In
contrast, bromoenol lactone (BEL), which inhibits phosphatidic acid phosphohydrolase
(PAP) activity and prevents the incorporation of palmitate into DAG, and Calphostin C, a
potent inhibitor of DAG-sensitive PKC isoforms, both blocked palmitate-dependent IκBα
phosphorylation (Figures 2C and 2D).
We next attempted to use an siRNA approach to identify a specific PKC isoform that might
be responsible for the palmitate effect. However, initial studies showed that downregulation
of individual isoforms was largely ineffective, suggesting redundancy in the function of
multiple PKCs. We therefore used an alternate approach to test whether the palmitate
response depends on the group of DAG-responsive, conventional/novel PKC isoforms, or on
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the group of ceramide-responsive, atypical PKCs. This approach made use of the well-
known ability of 12-O-tetradecanoylphorbol-13--acetate (TPA) to selectively downregulate
DAG-responsive PKC isoforms after prolonged exposure. As expected, upon treating cells
overnight with TPA, we found that levels of PKCδ, an example of a DAG-responsive
isoform, were almost undetectable, while levels of PKCζ, an example of an atypical PKC,
were completely unaltered (Figure 2E). Importantly, this TPA pre-treatment completely
abolished palmitate-dependent IκBα phosphorylation (Figure 2E). Taken together, the
results from the use of enzymatic inhibitors and TPA-mediated PKC downregulation suggest
that DAG generation, but not ceramide generation, and subsequent activation of classic/
novel PKC isoforms are critical for palmitate’s ability to stimulate canonical NF-κB
signaling in hepatocytes.
Bcl10 is required for palmitate-dependent NF-κB stimulation in hepatocytes
The CBM signalosome, composed of the proteins CARMA1/3, Bcl10 and MALT1, is
assembled in response to cell-surface receptor dependent PKC activation, and mediates
downstream canonical NF-κB activation. Thus, the signalosome functions as a bridge
linking PKC to the NF-κB machinery, but to date this has only been demonstrated
physiologically in the context of stimulating a select group of receptors that include the
lymphocyte antigen receptors and a subset of G protein-coupled receptors (GPCRs)
(Blonska and Lin, 2011; Wegener and Krappmann, 2007). Since our data indicated that PKC
activation is required for palmitate to stimulate IκBαpalmitate-dependent PKC activation to
stimulation of NF-κB, but in a unique, receptor-independent fashion. First, we demonstrated
that siRNA-mediated depletion of Bcl10, a central linker protein required for assembly of
the signalosome, prevents palmitate-dependent stimulation of IκBα phosphorylation in
HepG2 cells (Figures 3A and S3A). This effect of Bcl10 depletion was also observed in rat
H4IIE hepatoma cells, demonstrating that the requirement of Bcl10 is not a peculiarity of the
HepG2 cells and is not a species-specific phenomenon (Figure 3B). Bcl10 knockdown also
blocked palmitate-dependent phosphorylation of the RelA NF-κB subunit on Ser536 (Figure
3C). This phosphorylation event occurs as a consequence of IKKβ activation and contributes
to optimal activity of the canonical NF-κB transcription factor (O’Mahony et al., 2004;
Sakurai et al., 1999). Importantly, we found that role of Bcl10 in mediating a response to
palmitate is relatively specific for the NF-κB pathway, since Bcl10 knockdown had only a
slight effect on JNK1/2 phosphorylation (Figures 3C and S3B).
Next, we evaluated the contribution of the other principal components of the CBM
signalosome, using a knockdown strategy. CARMA3 depletion was effective at blocking
palmitate-dependent IκBα phosphorylation, but we were surprised to find that MALT1
depletion was inconsequential (Figure 3D). In fact, in many experiments the level of IκBα
phosphorylation was somewhat higher in the absence of MALT1.
We then investigated the role of Bcl10 in FFA-dependent NF-κB activation in hepatocytes
in vivo. First, we found that wild-type (WT) mice on a high saturated fat diet (HFD)
responded with a peak of NF-κB activation in liver, as measured by p-RelA induction, after
about three days (Figure S3C). Strikingly, HFD did not elicit this response in Bcl10-
deficient (Bcl10−/−) mice (Figure 3E). JNK activation in livers was variable during the
course of the brief HFD, without obvious differences between WT and Bcl10−/− mice
(Figure S3D). However, given that Bcl10 knockdown in cultured hepatocytes had a slight
impact on palmitate-dependent JNK1/2 phosphorylation (Figures 3C and S3B), we cannot
completely rule out the possibility that differences in JNK responsiveness may exist between
WT and Bcl10−/− mice at some point during HFD and ultimately influence insulin
sensitivity in liver.
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Bcl10 deficiency protects against high-fat diet induced insulin resistance
In the hepatocyte, insulin receptor stimulation leads to phosphorylation of the receptor
substrate proteins, IRS1 and IRS2, which then coordinate phosphatidylinositol 3-kinase
(PI3-kinase)-dependent activation of Akt (Taniguchi et al., 2006). One major function of
activated Akt is to then direct the downregulation of genes required for gluconeogenesis.
Several recent studies suggest that FFA-induced NF-κB activation contributes to hepatic
insulin resistance via inhibitory cross-talk within the hepatocyte, resulting in blockade of
specific steps in downstream insulin signaling pathways (Arkan et al., 2005; Cai et al., 2005;
Kim et al., 2001; Yuan et al., 2001). Consistent with this notion, we found that palmitate
pre-treatment of HepG2 cells caused a concentration- and time-dependent inhibition of
insulin-responsive Akt phosphorylation, an effect that temporally followed NF-κB
activation (Figures 4A and S4A). However, this effect of palmitate was not reversed by
myriocin, cycloserine, or fumonisin B1, inhibitors of ceramide synthesis (Figure S4B). In
contrast, siRNA-mediated depletion of Bcl10 did reverse the palmitate-dependent inhibition,
restoring insulin sensitivity to the cells as measured by Akt phosphorylation (Figure 4B).
These results indicate that Bcl10 is required for palmitate to inhibit insulin signaling, and
implicate Bcl10 as a novel factor in promoting hepatocellular insulin resistance.
We next evaluated the contribution of Bcl10 to insulin resistance in vivo. We performed
glucose tolerance tests (GTTs) with WT or Bcl10−/− mice that had been fed either a 60%
HFD for 1 week or a 45% HFD for 6 weeks. While weight gain was not significantly
different between the WT and Bcl10−/− groups (Figure S4C), this analysis revealed that
under both diets, Bcl10−/− mice maintained better glucose control throughout the GTTs
compared to WT mice (Figures 4C and 4E). Importantly, Bcl10−/− mice achieved better
glucose control with less insulin production, indicating that the effect of Bcl10 deficiency is
to protect the mice from HFD-induced insulin resistance (Figures 4D and 4F). These
analyses demonstrate that Bcl10 plays a central role in the development of HFD-induced
insulin resistance, in vivo.
DISCUSSION
Excess FFAs are key to the pathogenesis of the metabolic syndrome and likely play a role in
both the acute insulin resistance seen after short-term high fat feeding, and the chronic
insulin resistance associated with obesity. FFAs activate various signaling pathways that
inhibit the intracellular actions of insulin; chief among these is the NF-κB pathway.
Nevertheless, the mechanisms by which FFAs activate NF-κB are incompletely understood
and probably vary depending on the target cell type.
We have identified a novel mechanism by which palmitate activates NF-κB in hepatocytes.
In this case, activation depends upon intracellular accumulation of palmitate, metabolism to
DAG, and activation of conventional/novel PKCs. Our data also demonstrate a critical
downstream role for Bcl10 and CARMA3, supporting a model whereby activated PKC then
stimulates the CARMA-Bcl10-MALT1 (CBM) signalosome, a signaling complex that until
now has only been associated with cell surface receptor-dependent signaling to NF-κB
(Wegener and Krappmann, 2007). One critical difference, however, is highlighted by the
fact that MALT1 is completely dispensable for the palmitate response. This suggests that
palmitate signaling to NF-κB is not completely analogous to the now classically understood
mechanism whereby selected cell surface receptors (eg, TCR, AGTR1) signal to NF-κB. In
the later case, signaling proceeds through the CBM signalosome with MALT1 acting as an
obligatory effector protein, coordinating the downstream activation of the NF-κB
machinery. In the case of palmitate, signaling proceeds to NF-κB through CARMA3 and
Bcl10, but in a way that bypasses MALT1. This observation suggests that Bcl10 may have
unexplored functions related to canonical NF-κB activation that, with certain stimuli, do not
Van Beek et al. Page 6
Cell Rep. Author manuscript; available in PMC 2012 June 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
involve MALT1. Evidence for this concept can also be seen from work on Malt1−/− mice
which do not completely phenocopy Bcl10−/− mice with respect to BCR-dependent NF-κB
signaling (Ruland et al., 2003). Similarly, retinoic acid inducible gene I (RIG-1)-responsive
cytokine production appears to depend on Bcl10 and subsequent NF-κB activation, but not
on MALT1 (Poeck et al., 2010). Deciphering the MALT1-independent functions of Bcl10
will represent a major new frontier for the field of NF-κB signaling research.
Work presented here represents a paradigm shift in our understanding of how at least some
components of the CBM signalosome can be engaged. Specifically, the findings suggest that
coupling of CBM components at cell-surface receptor microdomains does not necessarily
need to occur for downstream NF-κB activation. Additional work will be needed to fully
determine how CARMA3, which is known to connect the signalosome with receptors and is
the predominant CARMA family member expressed in non-immune cells, can be stimulated
by palmitate metabolism and in the absence of receptor engagement. Since this signaling
cascade likely occurs in the cytoplasm, and not at the cell surface, it is intriguing to
speculate that the related CARD9 protein is also required; this scaffolding protein is
structurally similar to CARMA3 and can be regulated by PKC, but lacks domains that are
needed for membrane localization (Hara and Saito, 2009; Strasser et al., 2012). Although it
has mostly been studied in myeloid cells, perhaps CARD9 could work in concert with
CARMA3 to mediate the palmitate response in hepatocytes.
Our studies highlight the acute effects of FFAs on hepatocellular function and reveal a new
mechanism by which short-term high fat feeding impacts systemic insulin sensitivity. These
studies also underscore the notion that liver is one of the earliest sites affected by nutrient
imbalance, in the form of excess dietary fat. We propose a model for hepatic insulin
resistance during high fat feeding and subsequent obesity that takes into account both 1)
acute effects of excess fat as a pathologic dietary nutrient and 2) chronic effects that involve
the participation of inflammatory cells and the recently identified contribution of the
inflammasome (Figure S4D). This model suggests that FFAs act through varied mechanisms
that depend on both the cell type affected and the temporal stage in the development of
insulin resistance. A more complete understanding of the pathogenesis of insulin resistance
will require an understanding of how these varied mechanisms work in an integrated manner
over time.
EXPERIMENTAL PROCEDURES
Mice
Bcl10−/− mice have been described (Ruland et al., 2001). Mice were backcrossed onto the
C57BL/6J background for more than 10 generations and were used between 2–3 months of
age for all experiments involving HFD.
Fatty Acid Preparation and Treatment
FFAs were prepared as described previously (Cousin et al., 2001). Briefly, a 100mM stock
of palmitate (Sigma; Cat. No. P5585) was prepared in 0.1 M NaOH by heating to 70°C.
Palmitate was then complexed with BSA to make a 5mM working stock via dropwise
addition to 10% endotoxin/FA-free Fraction V BSA (MP Biomedicals; Cat. No. 194772),
while vortexing. The palmitate/BSA mixture was sterile filtered (0.2μM pore size) before
use.
Cell Culture and Western Analysis
Human hepatocellular carcinoma (HepG2) cells and H4IIE rat hepatocytes were obtained
from ATCC and maintained in DMEM with 10% FBS. MonoMac-6 cells were cultured in
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RPMI with 10% FBS. Cells were treated and analyzed as detailed in the Supplemental
Information.
RNA Interference
Cells were reverse transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen).
Specific siRNA reagents are listed in the Supplemental Information.
Ceramide Quantification
Cells were extracted with a mixture of methanol and chloroform, including internal
standards (D31-C16, C17, and C25 ceramide). Extractions were then dried under nitrogen
gas and reconstituted in 100 μl of mobile phase B (60:40 acetonitrile:isopropanol). Analyses
were carried out using liquid chromatography-triple quadrupole mass spectrometry (LC-
QQQ) in the University of Michigan Lipidomics Core Lab, and data analyzed using the
Agilent masshunter suite of programs, version B.04.00.
High Fat Diet Studies
Male WT or Bcl10−/− mice were fed high fat chow from Research Diets, Inc. containing
either 60% calories from fat (D12492) for 1 week, or 45% calories from fat (D12451) for 6
weeks. GTTs were performed following a 6 hour fast by administering IP glucose (1.5g/kg).
Blood glucose levels were measured using the OneTouch Ultra 2 glucose meter (Lifescan).
Serum insulin was measured by ELISA (Crystal Chem, Inc., Cat No. 90080), 15 minutes
into the GTT.
Statistics
Data are expressed as mean ± SEM. Differences between groups were compared using
unpaired Student’s t tests. P values of < 0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Palmitate activates hepatocellular NF-κB through CARMA3 and Bcl10, but not
MALT1
• Palmitate-dependent DAG/PKC activation triggers the Bcl10-containing
signalosome
• Bcl10 knockdown restores insulin sensitivity in hepatocytes exposed to
palmitate
• Bcl10 deficient mice are protected from insulin resistance during high fat diet
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Figure 1. Palmitate-dependent NF-κB Activation in Hepatocytes
(A and B) Time course for canonical NF-κB pathway activation in HepG2 cells following
palmitate (FFA) treatment.
(C) Effect of IKK2 inhibitor VI (10 μM), an inhibitor of the canonical pathway kinase,
IKKβ, on palmitate (FFA)-dependent NF-κB activation.
(D) Effect of IKKβ knockdown on palmitate (FFA) -dependent NF-κB activation.
(E and F) Palmitate (FFA) -dependent NF-κB activation in HepG2 cells in the absence or
presence of either 10 μg/ml TLR4 blocking antibody (E) or 50 ng/ml IL-1R antagonist (F).
See also Figure S1.
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Figure 2. Hepatocellular Palmitate Metabolism and the Impact on NF-κB Activation
(A) Schematic of palmitate metabolism.
(B) Lack of an effect of myriocin (10 μM), a ceramide synthesis inhibitor, on palmitate
(FFA) -dependent NF-κB activation in HepG2 cells (upper panel). Cellular levels of three
ceramide species (C16, C18, and C20) were induced by palmitate treatment, but induction of
all three was blocked by myriocin (lower panel).
(C and D) Effect of DAG synthesis inhibition by BEL (C) or of blocking DAG-sensitive
PKC isoforms with Calphostin C (D) on the palmitate (FFA) response.
(E) Overnight pre-treatment of HepG2 cells with TPA caused downregulation of DAG-
sensitive PKCs (eg, PKCδ), but not atypical PKCs (eg, PKCζ), and prevented palmitate
(FFA) -dependent NF-κB activation. As expected, TPA pre-treatment also prevented NF-κB
activation in response to Ang II.
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See also Figure S2.
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Figure 3. Bcl10 is a Critical Mediator of FFA-dependent NF-κB Activation in liver
(A and B) Bcl10 knockdown by siRNA in either human HepG2 (A) or rat 4IIE (B)
hepatocytes blocks palmitate (FFA) -dependent NF-κB activation. Activation by Ang II (1
μM) was included as a positive control, while activation by IL-1β (10 ng/ml) and TNFα (1
ng/ml) were used as negative controls to demonstrate the selective impact of Bcl10
knockdown on only certain pathways of IKK activation.
(C) Bcl10 knockdown blocked RelA phosphorylation, another marker of NF-κB activation,
but did not significantly impact JNK activation.
(D) Effect of siRNA-mediated knockdown, in HepG2 cells, of each component of the CBM
signalosome. CARMA3 knockdown, but not MALT knockdown, impaired the palmitate
(FFA) response.
(E) NF-κB activation in livers taken from WT or Bcl10−/− mice following 3 days on either a
normal diet (ND) or a 60% HFD.
See also Figure S3.
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Figure 4. Bcl10 Deficiency Protects from HFD-induced Insulin Resistance
(A) Palmitate (FFA) -dependent inhibition of insulin signaling in HepG2 cells.
(B) Bcl10 knockdown by siRNA in HepG2 cells restores insulin sensitivity in the face of
palmitate (FFA) pre-treatment.
(C and E) GTTs following 1 week (C) on normal diet (ND) vs 60% HFD (n= 3–7 per
group), or following 6 weeks (E) on ND vs 45% HFD (n= 4–10 per group). Data are mean ±
SEM. *p<0.05. (D and F) Plasma insulin levels during GTTs. Data are mean ± SEM.
**p<0.01.
See also Figure S4.
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